Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -47.78% is in line with its 4-year average of -50.82%, around the middle of its 4-year range (-69.23%–-23.52%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.50% above its 12-month average of -53.38%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -47.78%.
RETURN ON EQUITY (ROE)
-47.78%
RETURN ON EQUITY (ROE) AVG TTM
-53.38%
RETURN ON EQUITY (ROE) AVG 3Y
-57.14%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.50%
CURRENT VS 3Y AVG
+16.38%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-32.71%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$202.05M
Return on Equity (ROE)
-47.78%
TTM Avg
-53.38%
3Y Avg
-57.14%
5Y Avg
N/A
Market Cap
$206.61M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.97M
Return on Equity (ROE)
-136.83%
TTM Avg
-43.45%
3Y Avg
-452.04%
5Y Avg
-306.86%
Market Cap
$218.42M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$184.12M
Return on Equity (ROE)
-19.01%
TTM Avg
-54.50%
3Y Avg
-75.60%
5Y Avg
-59.28%
Market Cap
$220.94M
Return on Equity (ROE)
N/A
TTM Avg
-280.12%
3Y Avg
-179.90%
5Y Avg
-133.80%
Market Cap
$179.70M
Return on Equity (ROE)
-21.57%
TTM Avg
-470.91%
3Y Avg
-299.18%
5Y Avg
-180.76%
Market Cap
$176.96M
Return on Equity (ROE)
-7104.24%
TTM Avg
-166.54%
3Y Avg
-137.65%
5Y Avg
-112.46%
Market Cap
$174.17M
Return on Equity (ROE)
-116.42%
TTM Avg
-18.43%
3Y Avg
-136.68%
5Y Avg
-137.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $202.05M | -47.78% | -53.38% | -57.14% | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -136.83% | -43.45% | -452.04% | -306.86% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 39.66% | 4.24% | -15.88% | -20.06% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -19.01% | -54.50% | -75.60% | -59.28% |
| Alector, Inc. (ALEC)vs › | $220.94M | N/A | -280.12% | -179.90% | -133.80% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -21.57% | -470.91% | -299.18% | -180.76% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -7104.24% | -166.54% | -137.65% | -112.46% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -116.42% | -18.43% | -136.68% | -137.61% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -215.26% | -150.35% | 8.65% | -35.35% |
ROE
-47.8%
ROA
-44.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -47.78% |
| 2026-03-31 | -42.26% |
| 2025-12-31 | -66.29% |
| 2025-09-30 | -56.29% |
| 2025-06-30 | -54.30% |
| 2025-03-31 | -61.85% |
| 2024-12-31 | -62.70% |
| 2024-09-30 | -69.23% |
| 2024-06-30 | -65.74% |
| 2024-03-31 | -59.70% |
| 2023-12-31 | -51.91% |
| 2023-09-30 | -42.94% |
| 2023-06-30 | -61.88% |
| 2023-03-31 | -58.93% |
| 2022-12-31 | -42.94% |
| 2022-09-30 | -34.72% |
| 2022-06-30 | -27.85% |
| 2022-03-31 | -23.52% |
| 2021-12-31 | -34.80% |
